Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 383.53M P/E - EPS this Y 7.70% Ern Qtrly Grth -
Income -92.95M Forward P/E -3.68 EPS next Y 22.20% 50D Avg Chg 17.00%
Sales 33.9M PEG - EPS past 5Y - 200D Avg Chg 29.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -49.00%
Recommedations 2.00 Quick Ratio 3.97 Shares Outstanding 42.59M 52W Low Chg 103.00%
Insider Own 24.78% ROA -20.46% Shares Float 21.37M Beta 3.15
Inst Own 62.28% ROE - Shares Shorted/Prior 1.32M/1.19M Price 9.17
Gross Margin -210.47% Profit Margin -274.23% Avg. Volume 87,751 Target Price 13.75
Oper. Margin -558.30% Earnings Date Aug 2 Volume 51,216 Change -1.50%
About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc. News
05/09/24 Foghorn Therapeutics Inc. (NASDAQ:FHTX) Just Reported, And Analysts Assigned A US$11.67 Price Target
05/07/24 Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
05/06/24 Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
05/06/24 Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates
05/06/24 Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
04/16/24 Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
04/09/24 Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
04/09/24 Foghorn Therapeutics (NASDAQ:FHTX) Is In A Good Position To Deliver On Growth Plans
04/05/24 Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
04/02/24 Does Foghorn Therapeutics (FHTX) Have the Potential to Rally 105.75% as Wall Street Analysts Expect?
03/26/24 Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
03/13/24 Foghorn Therapeutics Inc. (FHTX) Upgraded to Buy: Here's What You Should Know
03/13/24 Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
03/07/24 Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
03/07/24 Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
03/05/24 Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
02/28/24 Silence Therapeutics PLC Sponsored ADR (SLN) Soars 6.4%: Is Further Upside Left in the Stock?
02/28/24 Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
02/12/24 Foghorn Therapeutics Inc. (FHTX) Moves 22.7% Higher: Will This Strength Last?
02/09/24 Foghorn (FHTX) Jumps 55% as Lilly Takes Up FHD-909 Development
FHTX Chatroom

User Image Stock_Titan Posted - 1 week ago

$FHTX Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update https://www.stocktitan.net/news/FHTX/foghorn-therapeutics-provides-first-quarter-2024-financial-and-n4t259td67b3.html

User Image jacky1230 Posted - 04/24/24

$FHTX winning. Selling 20%

User Image jacky1230 Posted - 04/23/24

$FHTX avg down 5.38 Less powder left. No fear at all Chilling as always

User Image jacky1230 Posted - 04/22/24

$FHTX avg down 5.68 Not sweating a bit. Go on chilling and chilled

User Image jacky1230 Posted - 04/19/24

$FHTX unbothered and unshaken. Cool as a Coolio This not gonna go under 5. It’s not gonna

User Image jacky1230 Posted - 4 weeks ago

$FHTX avg 6.12 now Ain’t panic Ain’t flustered This can’t go any lower

User Image jacky1230 Posted - 1 month ago

$FHTX hardly concerned at all. 6.36 avg. chilling like a fox

User Image jacky1230 Posted - 1 month ago

Ain’t no fear $FHTX

User Image jacky1230 Posted - 1 month ago

$FHTX avg down 6.36 Still got some powder to avg down if need be. No fear at all. If ever 5.5 I will add more.

User Image jacky1230 Posted - 1 month ago

$FHTX :

User Image jacky1230 Posted - 1 month ago

$FHTX avg down to 6.75 avg. still got some powder to avg down more. Under 5.9, I add more Not scared. Cool and chilled

User Image briefingcom Posted - 1 month ago

$FHTX: Foghorn Therapeutics announced that Kristian Humer will join the company as CFO on April 16, 2024 https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240416070745FHTX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image jacky1230 Posted - 1 month ago

$FHTX so not scared This can’t be under $6

User Image sonyforxyz Posted - 1 month ago

$FHTX 6.5 first

User Image jacky1230 Posted - 1 month ago

$FHTX 6.95 we buy

User Image Stock_Titan Posted - 1 month ago

$FHTX Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs https://www.stocktitan.net/news/FHTX/foghorn-therapeutics-presents-new-preclinical-data-on-potential-z6tgs0eh2jpr.html

User Image RallyRaider Posted - 1 month ago

$FHTX very nice action... soon they will have to discuss: why not move a little faster if all agree?

User Image sophi1258 Posted - 1 month ago

$FHTX my followers are at 6.68 avg Unfazed

User Image sophi1258 Posted - 1 month ago

$FHTX silly!

User Image sonyforxyz Posted - 1 month ago

$FHTX 6.5 I will buy

User Image jacky1230 Posted - 1 month ago

$FHTX sold 30%

User Image Stock_Titan Posted - 1 month ago

$FHTX Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference https://www.stocktitan.net/news/FHTX/foghorn-therapeutics-to-participate-in-needham-s-23rd-annual-virtual-g2ltxfys4qzm.html

User Image jacky1230 Posted - 1 month ago

$FHTX still ain’t. Ain’t no worry

User Image RallyRaider Posted - 1 month ago

$FHTX can ignore sector weakness, is behaving well. Silently doing its own thing.

User Image jacky1230 Posted - 1 month ago

$FHTX unfazed and confident This ain’t going under 7

User Image RollingDollar Posted - 1 month ago

$FHTX

User Image sophi1258 Posted - 1 month ago

$FHTX my neighbor is still giddily rocking

User Image jacky1230 Posted - 03/30/24

$FHTX sold some at 6.7 Unless under 5.88, I’d keep my shares

User Image sophi1258 Posted - 03/26/24

$FHTX my neighbor Pamela is at 5.52 avg She is nonchalant and giddy

User Image Stock_Titan Posted - 03/26/24

$FHTX Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting https://www.stocktitan.net/news/FHTX/foghorn-to-host-conference-call-and-webcast-on-pipeline-of-potential-reg65jgt6jk3.html

Analyst Ratings
HC Wainwright & Co. Buy May 7, 24
HC Wainwright & Co. Buy May 1, 24
Wedbush Outperform Apr 10, 24
HC Wainwright & Co. Buy Apr 10, 24
Wedbush Outperform Mar 8, 24
Morgan Stanley Equal-Weight Nov 13, 23
HC Wainwright & Co. Buy Aug 7, 23
Morgan Stanley Equal-Weight Jul 6, 23
Goldman Sachs Buy Jun 29, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GILL SIMBA Director Director Sep 12 Option 0.73 82,000 59,860 82,000 09/14/22
Bellon Steven F. Chief Scientific Off.. Chief Scientific Officer Aug 11 Option 3.72 1,858 6,912 121,957 08/15/22